Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 4/2012

01.04.2012 | Review

Nontuberculous mycobacteria infection in solid organ transplant recipients

verfasst von: C. Piersimoni

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Although advances in surgical technique, drug-induced immunosuppression, and supportive medical therapy have led to improved survival and quality of live after solid organ transplantations, infections still represent a major threat for transplant recipients.
Infections with non tuberculous mycobacteria (NTM) are infrequent, but can be associated with relevant morbidity and mortality. With the exception of few comprehensive studies, the available literature consists predominantly of case reports and institutional experiences. This article reviews NTM infection in the setting of solid organ transplant (SOT) recipients dealing with clinical features, diagnosis, treatment and outcome. Published studies have documented a protean presentation of NTM infection in SOT recipients which may include skin and soft tissue lesions, osteoarticular infections and pleuropulmonary disease. An aggressive approach including histopathologic examination and acid-fast bacilli culture of aspirates or biopsy specimens from involved sites are essential for diagnosis. A combined treatment of debridement surgery, reduction of immunosuppressive medications and/or antimycobacterial drugs is frequently associated with a favorable outcome. It is strongly emphasized that a high index of suspicion for NTM infection should be maintained when managing SOT recipients with unusual clinical manifestations. Early diagnosis and initiation of therapy are essential to prevent morbidity and mortality in this vulnerable population.
Literatur
1.
Zurück zum Zitat Alangaden GJ, Chandrasekar P, Samuel R, Bettiker RL, Truant AL, Jungkind D et al (2008) Cumitech 45: Infections in solid organ transplant recipients. Truant AL (ed) American Society for Microbiology, Washington D.C. Alangaden GJ, Chandrasekar P, Samuel R, Bettiker RL, Truant AL, Jungkind D et al (2008) Cumitech 45: Infections in solid organ transplant recipients. Truant AL (ed) American Society for Microbiology, Washington D.C.
2.
Zurück zum Zitat Rubin RH (2002) The direct and indirect effects of infection in liver transplantation: pathogenesis, impact and clinical management. Curr Clin Top Infect Dis 22:125–154PubMed Rubin RH (2002) The direct and indirect effects of infection in liver transplantation: pathogenesis, impact and clinical management. Curr Clin Top Infect Dis 22:125–154PubMed
3.
4.
Zurück zum Zitat Wolinsky E (1979) Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 119:107–159PubMed Wolinsky E (1979) Nontuberculous mycobacteria and associated diseases. Am Rev Respir Dis 119:107–159PubMed
5.
Zurück zum Zitat Falkinham JO (1996) Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 9:177–215PubMed Falkinham JO (1996) Epidemiology of infection by nontuberculous mycobacteria. Clin Microbiol Rev 9:177–215PubMed
6.
Zurück zum Zitat Tortoli E (2003) Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 16:319–354PubMedCrossRef Tortoli E (2003) Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 16:319–354PubMedCrossRef
7.
Zurück zum Zitat Wood GL, Washington JA II (1987) Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects. Rev Infect Dis 9:275–294CrossRef Wood GL, Washington JA II (1987) Mycobacteria other than Mycobacterium tuberculosis: review of microbiologic and clinical aspects. Rev Infect Dis 9:275–294CrossRef
8.
Zurück zum Zitat Herdman AV, Steele JCH (2004) The new mycobacterial species. Emerging or newly distinguished pathogens. Clin Lab Med 24:651–690PubMedCrossRef Herdman AV, Steele JCH (2004) The new mycobacterial species. Emerging or newly distinguished pathogens. Clin Lab Med 24:651–690PubMedCrossRef
9.
Zurück zum Zitat Doucette K, Fishman JA (2004) Nontuberculous mycobacterial infection in hemopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 38:1428–1439PubMedCrossRef Doucette K, Fishman JA (2004) Nontuberculous mycobacterial infection in hemopoietic stem cell and solid organ transplant recipients. Clin Infect Dis 38:1428–1439PubMedCrossRef
10.
Zurück zum Zitat Marras TK, Chedore P, Ying AM, Jamieson F (2007) Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003. Thorax 62:661–666PubMedCrossRef Marras TK, Chedore P, Ying AM, Jamieson F (2007) Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003. Thorax 62:661–666PubMedCrossRef
11.
Zurück zum Zitat Khan K, Wang J, Marras TK (2007) Nontuberculous mycobacteria sensitization in the United States: national trends over three decades. Am J Crit Care Med 176:306–313CrossRef Khan K, Wang J, Marras TK (2007) Nontuberculous mycobacteria sensitization in the United States: national trends over three decades. Am J Crit Care Med 176:306–313CrossRef
12.
Zurück zum Zitat Daley C (2009) Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment. Curr Opin Org Transpl 4:619–624CrossRef Daley C (2009) Nontuberculous mycobacterial disease in transplant recipients: early diagnosis and treatment. Curr Opin Org Transpl 4:619–624CrossRef
13.
Zurück zum Zitat Escalante P (2007) Mycobacterial infections in solid organ transplantation. Curr Opin Organ Trasplant 12:585–590CrossRef Escalante P (2007) Mycobacterial infections in solid organ transplantation. Curr Opin Organ Trasplant 12:585–590CrossRef
14.
Zurück zum Zitat Garrison AP, Morris ML, Doblecki LS, Smith L, Cleary TJ et al (2009) Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature. Transpl Infect Dis 11:541–548PubMedCrossRef Garrison AP, Morris ML, Doblecki LS, Smith L, Cleary TJ et al (2009) Mycobacterium abscessus infection in solid organ transplant recipients: report of three cases and review of the literature. Transpl Infect Dis 11:541–548PubMedCrossRef
15.
Zurück zum Zitat Dorman S (2004) Nontuberculous mycobacteria. Am J Transplant 4(suppl 10):42–46 Dorman S (2004) Nontuberculous mycobacteria. Am J Transplant 4(suppl 10):42–46
16.
Zurück zum Zitat American Thoracic Society (2007) Diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. Am J Respir Crit Care Med 175:367–416 American Thoracic Society (2007) Diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. Am J Respir Crit Care Med 175:367–416
17.
Zurück zum Zitat Field SK, Cowie RL (2006) Lung disease due the more common nontuberculous mycobacteria. Chest 129:1653–1672PubMedCrossRef Field SK, Cowie RL (2006) Lung disease due the more common nontuberculous mycobacteria. Chest 129:1653–1672PubMedCrossRef
18.
Zurück zum Zitat Chalemskurlat W, Sood N, Neuringer IP, Hecker TM, Chang L, Rivera MP et al (2006) Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 61:507–513CrossRef Chalemskurlat W, Sood N, Neuringer IP, Hecker TM, Chang L, Rivera MP et al (2006) Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 61:507–513CrossRef
19.
Zurück zum Zitat Haas S, Scully B, Cohen J (2005) Mycobacterium avium complex infection in kidney transplant patients. Transpl Infect Dis 7:75–79PubMedCrossRef Haas S, Scully B, Cohen J (2005) Mycobacterium avium complex infection in kidney transplant patients. Transpl Infect Dis 7:75–79PubMedCrossRef
20.
Zurück zum Zitat Malouf MA, Glanville AR (1999) The spectrum of mycobacterial infections after lung transplantation. Am J Crit Care Med 160:1611–1616 Malouf MA, Glanville AR (1999) The spectrum of mycobacterial infections after lung transplantation. Am J Crit Care Med 160:1611–1616
21.
Zurück zum Zitat Patel R, Paya CV (1997) Infections in solid-organ transplant recipients. Clin Microbiol Rev 10:86–124PubMed Patel R, Paya CV (1997) Infections in solid-organ transplant recipients. Clin Microbiol Rev 10:86–124PubMed
22.
Zurück zum Zitat Young JH, Weisdorf DJ (2010) Typical and atypical Mycobacterium infections after hematopoietic stem cell or solid organ transplantation. In: Bowden RA, Ljungman P, Snydman DR (eds) Transplant infections, 3rd edn. Lippincott, Williams & Wilkins, Philadelphia, pp 282–294 Young JH, Weisdorf DJ (2010) Typical and atypical Mycobacterium infections after hematopoietic stem cell or solid organ transplantation. In: Bowden RA, Ljungman P, Snydman DR (eds) Transplant infections, 3rd edn. Lippincott, Williams & Wilkins, Philadelphia, pp 282–294
23.
Zurück zum Zitat Patel R, Roberts GD, Keating MR, Paya CV (1994) Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis 19:263–273PubMedCrossRef Patel R, Roberts GD, Keating MR, Paya CV (1994) Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis 19:263–273PubMedCrossRef
24.
Zurück zum Zitat Dorman S, Subramanian A (2009) Nontuberculous mycobacteria in solid organ transplant recipients. Am J Transplant 9(suppl 4):S63–S69PubMedCrossRef Dorman S, Subramanian A (2009) Nontuberculous mycobacteria in solid organ transplant recipients. Am J Transplant 9(suppl 4):S63–S69PubMedCrossRef
25.
Zurück zum Zitat Fan MH, Hadjiliadis D (2009) Incidence and management of mycobacterial infections in solid organ transplant recipients. Curr Infect Dis Rep 11:216–222PubMedCrossRef Fan MH, Hadjiliadis D (2009) Incidence and management of mycobacterial infections in solid organ transplant recipients. Curr Infect Dis Rep 11:216–222PubMedCrossRef
26.
Zurück zum Zitat Martìn-Penagos M, Rodrigo E, Ruiz JC, Agüero J, Fernandez-Mazarrasa C et al (2009) Lung cavitation due to Mycobacterium xenopi in a renal transplant recipient. Transpl Infect Dis 11:249–252PubMedCrossRef Martìn-Penagos M, Rodrigo E, Ruiz JC, Agüero J, Fernandez-Mazarrasa C et al (2009) Lung cavitation due to Mycobacterium xenopi in a renal transplant recipient. Transpl Infect Dis 11:249–252PubMedCrossRef
27.
Zurück zum Zitat Thaunat O, Morelon E, Stern M, Buffet P, Offredo C, Mamzer-Bruneel MF, Kreis H (2004) Mycobacterium xenopi pulmonary infection in two renal transplant recipients under sirolimus therapy. Transpl Infect Dis 6:179–182PubMedCrossRef Thaunat O, Morelon E, Stern M, Buffet P, Offredo C, Mamzer-Bruneel MF, Kreis H (2004) Mycobacterium xenopi pulmonary infection in two renal transplant recipients under sirolimus therapy. Transpl Infect Dis 6:179–182PubMedCrossRef
28.
Zurück zum Zitat Muñoz RM, Pulpòn LA, Yebra M, Segovia J, Gallego JC, Daz RM (2000) Intestinal involvement by nontuberculous mycobacteria after heart transplantation. Clin Infect Dis 30:603–605PubMedCrossRef Muñoz RM, Pulpòn LA, Yebra M, Segovia J, Gallego JC, Daz RM (2000) Intestinal involvement by nontuberculous mycobacteria after heart transplantation. Clin Infect Dis 30:603–605PubMedCrossRef
29.
Zurück zum Zitat Todd JL, Lakey J, Howell D, Reidy M, Zaas D (2007) Portal hypertension and granulomatous liver disease in a lung transplant recipient due to disseminated atypical mycobacterial infection. Am J Transpl 7:1300–1303CrossRef Todd JL, Lakey J, Howell D, Reidy M, Zaas D (2007) Portal hypertension and granulomatous liver disease in a lung transplant recipient due to disseminated atypical mycobacterial infection. Am J Transpl 7:1300–1303CrossRef
30.
Zurück zum Zitat Saubolle MA, Kiehn TE, White MH et al (1996) Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin Microbiol Rev 9:435–447PubMed Saubolle MA, Kiehn TE, White MH et al (1996) Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin Microbiol Rev 9:435–447PubMed
31.
Zurück zum Zitat Nurmohamed S, Weenink A, Moenilaram H, Visser C, Bemelman F (2007) Hyperammonemia in generalized Mycobacterium genavense infection after renal transplantation. Am J Transpl 7:722–723CrossRef Nurmohamed S, Weenink A, Moenilaram H, Visser C, Bemelman F (2007) Hyperammonemia in generalized Mycobacterium genavense infection after renal transplantation. Am J Transpl 7:722–723CrossRef
32.
Zurück zum Zitat Doggett JS, Strasfeld L (2011) Disseminated Mycobacterium genavense with pulmonary nodules in a kidney transplant recipient: case report and review of the literature. Transpl Infect Dis 13:38–43PubMedCrossRef Doggett JS, Strasfeld L (2011) Disseminated Mycobacterium genavense with pulmonary nodules in a kidney transplant recipient: case report and review of the literature. Transpl Infect Dis 13:38–43PubMedCrossRef
33.
Zurück zum Zitat Piersimoni C, Scarparo C (2008) Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients. Lancet Infect Dis 8:323–334PubMedCrossRef Piersimoni C, Scarparo C (2008) Pulmonary infections associated with non-tuberculous mycobacteria in immunocompetent patients. Lancet Infect Dis 8:323–334PubMedCrossRef
34.
Zurück zum Zitat Torre-Cisneiros J, De La Mata M, Rufian S, Villanueva Marcos JL, Aroca JG et al (1995) Importance of surveillance mycobacterial cultures after liver transplantation. Transplantation 60:1054–1055 Torre-Cisneiros J, De La Mata M, Rufian S, Villanueva Marcos JL, Aroca JG et al (1995) Importance of surveillance mycobacterial cultures after liver transplantation. Transplantation 60:1054–1055
35.
Zurück zum Zitat Cernoch PL, Enns RK, Saubolle MA, Wallace RJ Jr (1994) Cumitechs 16A: laboratory diagnosis of the mycobacterioses. Weissfeld AS (ed) American Society for Microbiology, Washington D.C. Cernoch PL, Enns RK, Saubolle MA, Wallace RJ Jr (1994) Cumitechs 16A: laboratory diagnosis of the mycobacterioses. Weissfeld AS (ed) American Society for Microbiology, Washington D.C.
36.
Zurück zum Zitat Thomsen VØ, Dragsted UB, Bauer J, Fuursted K, Lundgren J (1999) Disseminated infection with Mycobacterium genavense: a challenge to physicians and mycobacteriologists. J Clin Microbiol 37:3901–3905PubMed Thomsen VØ, Dragsted UB, Bauer J, Fuursted K, Lundgren J (1999) Disseminated infection with Mycobacterium genavense: a challenge to physicians and mycobacteriologists. J Clin Microbiol 37:3901–3905PubMed
37.
Zurück zum Zitat Realini L, van der Stuyft P, De Ridder K, Hirschel B, Portaels F (1997) Inhibitory effects of polyoxyethylene stearate, PANTA and neutral pH on growth of Mycobacterium genavense in BACTEC primary cultures. J Clin Microbiol 35:2791–2794PubMed Realini L, van der Stuyft P, De Ridder K, Hirschel B, Portaels F (1997) Inhibitory effects of polyoxyethylene stearate, PANTA and neutral pH on growth of Mycobacterium genavense in BACTEC primary cultures. J Clin Microbiol 35:2791–2794PubMed
38.
Zurück zum Zitat CLSI (2007) Laboratory detection and identification of mycobacteria; proposed guideline. M48-P. Clinical and Laboratory Standards Institute, Wayne, PA CLSI (2007) Laboratory detection and identification of mycobacteria; proposed guideline. M48-P. Clinical and Laboratory Standards Institute, Wayne, PA
39.
Zurück zum Zitat Wallace RJ Jr, Tanner D, Brannan PJ, Brown BA (1993) Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 119:482–486PubMed Wallace RJ Jr, Tanner D, Brannan PJ, Brown BA (1993) Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 119:482–486PubMed
40.
Zurück zum Zitat Wallace RJ Jr, Griffith DE, Oliver KN, Cook JL, Gordin F (1997) Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Crit Care Med 156:S1–S25 Wallace RJ Jr, Griffith DE, Oliver KN, Cook JL, Gordin F (1997) Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Crit Care Med 156:S1–S25
41.
Zurück zum Zitat CLSI (2011) Susceptibility testing of mycobacteria, nocardia and other aerobic actinomycetes. Approved standard, 2nd edn, CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA CLSI (2011) Susceptibility testing of mycobacteria, nocardia and other aerobic actinomycetes. Approved standard, 2nd edn, CLSI document M24-A2. Clinical and Laboratory Standards Institute, Wayne, PA
42.
Zurück zum Zitat Iseman MD, Fischer A (2008) Tumor necrosis factor-α at the intersection of mycobacterial immunity and pathogenesis: an important new address in medicine. Clin Infect Dis 46:1738–1740CrossRef Iseman MD, Fischer A (2008) Tumor necrosis factor-α at the intersection of mycobacterial immunity and pathogenesis: an important new address in medicine. Clin Infect Dis 46:1738–1740CrossRef
43.
Zurück zum Zitat Wallis RS (2008) Mycobacterial disease attributable to tumor necrosis factor-α blockers. Clin Infect Dis 47:1603–1605PubMedCrossRef Wallis RS (2008) Mycobacterial disease attributable to tumor necrosis factor-α blockers. Clin Infect Dis 47:1603–1605PubMedCrossRef
44.
Zurück zum Zitat Van Ingen J, Boerce MJ, Dekhuijzen R, van Soolingen D (2008) Mycobacterial disease in patients with rheumatic disease. Nat Clin Pract Rheumathol 4:649–656CrossRef Van Ingen J, Boerce MJ, Dekhuijzen R, van Soolingen D (2008) Mycobacterial disease in patients with rheumatic disease. Nat Clin Pract Rheumathol 4:649–656CrossRef
45.
Zurück zum Zitat Kesten S, Chaparro C (1999) Mycobacterial infections in lung transplant recipients. Chest 115:741–745PubMedCrossRef Kesten S, Chaparro C (1999) Mycobacterial infections in lung transplant recipients. Chest 115:741–745PubMedCrossRef
46.
Zurück zum Zitat Finch CK, Chrisman CR, Baciewicz AM, Self TH (2002) Rifampin and rifabutin drug interaction: an update. Arch Intern Med 162:958–992CrossRef Finch CK, Chrisman CR, Baciewicz AM, Self TH (2002) Rifampin and rifabutin drug interaction: an update. Arch Intern Med 162:958–992CrossRef
47.
Zurück zum Zitat Ferrari SL, Goffin E, Moraud M, Wallemacq P, Squiffiet JP, Pirsom Y (1994) The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation 58:725–727PubMed Ferrari SL, Goffin E, Moraud M, Wallemacq P, Squiffiet JP, Pirsom Y (1994) The interaction between clarithromycin and cyclosporine in kidney transplant recipients. Transplantation 58:725–727PubMed
48.
Zurück zum Zitat Piemmons RM, McAllister CL, Garces MC, Ward RL (1997) Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient. Case report and analysis of interactions among clarithromycin, rifampin and cyclosporine. Clin Infect Dis 24:995–997CrossRef Piemmons RM, McAllister CL, Garces MC, Ward RL (1997) Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient. Case report and analysis of interactions among clarithromycin, rifampin and cyclosporine. Clin Infect Dis 24:995–997CrossRef
Metadaten
Titel
Nontuberculous mycobacteria infection in solid organ transplant recipients
verfasst von
C. Piersimoni
Publikationsdatum
01.04.2012
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 4/2012
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-011-1329-4

Weitere Artikel der Ausgabe 4/2012

European Journal of Clinical Microbiology & Infectious Diseases 4/2012 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.